The Landmark 1999 Institute of Medicine Report: Medical Marijuana Has Promise but Smoking Is Not the Answer | Research

The takeaway

The IOM concluded that cannabinoids showed therapeutic promise for pain, nausea, and appetite but recommended against smoked marijuana in favor of developing a medical cannabinoid inhaler, while finding limited gateway and addiction risks.

Read this if you want to understand the most influential scientific assessment of medical marijuana ever conducted.

IOM found limited gateway and addiction risk from medical cannabinoid use

What the researchers found

Responding to public pressure, the Office of National Drug Control Policy funded a comprehensive study by the Institute of Medicine. The resulting report used scientific reviews, public hearings, and expert evaluation.

The key findings: cannabinoids showed therapeutic potential for pain, chemotherapy nausea, and appetite stimulation. But the report recommended against smoked marijuana as medicine due to the health risks of smoking.

Instead, the IOM recommended developing a medical cannabinoid inhaler that would deliver the rapid onset of smoking without combustion-related harm. For patients with immediate needs, compassionate use of marijuana under carefully reviewed protocols was recommended.

The report called for major research investment in cannabinoid biology, careful clinical trials, psychological effects analysis, and evaluation of heavy use consequences. On addiction and gateway concerns, the report found limited evidence that medical cannabinoid use would lead to widespread abuse or serve as a gateway to other drugs.

Why it matters

The IOM report was the most authoritative and comprehensive assessment of medical marijuana by a major scientific institution. Its conclusions influenced federal and state policy for decades and became the most-cited reference in medical marijuana debates.

The numbers in context

Therapeutic potential identified for pain, nausea, and appetite. Limited gateway and addiction risk. Recommended: cannabinoid inhaler development, research investment, compassionate use under protocols.

How the study worked

Comprehensive systematic evaluation by the Institute of Medicine, incorporating scientific literature reviews, public hearings, agency reports, and expert evaluation.

What this study cannot tell us

The report was constrained by the evidence available through the late 1990s. Its recommendation against smoked marijuana was partly superseded by vaporizer technology. The compassionate use recommendation was narrower than what state programs eventually implemented.

How to read the evidence

A comprehensive institutional review by the IOM, the gold standard for scientific policy assessment. The most authoritative evaluation of medical marijuana evidence conducted.

When this study was published

Published in 2000 (report issued 1999). This remains the most influential single assessment, though the evidence base has expanded enormously since.

The bigger picture

While the IOM recommended against smoked marijuana, its acknowledgment of therapeutic potential was seized upon by medical marijuana advocates, while opponents emphasized the "no smoking" recommendation. The recommended inhaler eventually materialized as cannabis vaporizers, though not through the pharmaceutical pathway the IOM envisioned.

Questions still open

Have the IOM's research recommendations been adequately funded and pursued? Has the cannabinoid inhaler been developed as recommended? How have the findings held up against two decades of subsequent research?

Common questions

What did the IOM conclude about medical marijuana?

Cannabinoids show therapeutic promise for pain, nausea, and appetite, but smoked marijuana is not recommended. Instead, a medical inhaler should be developed, and compassionate use should be allowed under careful protocols.

Is medical marijuana a gateway drug?

The IOM found limited evidence that medical cannabinoid use would lead to abuse of other substances or serve as a gateway drug.

Read the original research

Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report.

Archives of general psychiatry, 57(6), 547-52

View on PubMed ↗

Citation

Watson, S J; Benson, J A; Joy, J E. (2000). Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report.. Archives of general psychiatry, 57(6), 547-52.